Clinical Trials Browser

Phase 1/2 × OTHER × Prostatic Neoplasms × Clear all

NCT05888532 2026-03-17

64Cu-GRIP B in Patients With Advanced Malignancies

Phase 1/2 Recruiting

Kidney Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Lipodystrophy, Congenital Generalized

NCT04037254 2026-03-16

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

Phase 1/2 Completed

22 enrolled 13 charts

Prostatic Neoplasms

NCT03424850 2026-03-11

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT07182279 2026-03-09

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

Phase 1/2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT06066437 2026-03-05

NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT06237179 2026-03-02

EXTRA-PC

Phase 1/2 Recruiting

Motor Activity, Prostatic Neoplasms

NCT07441889 2026-03-02

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

Phase 1/2 Not yet recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT06085729 2026-02-27

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

Phase 1/2 Suspended

Prostatic Neoplasms

NCT02522715 2026-02-24

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 1/2 Active not recruiting

37 enrolled 10 charts

Prostatic Neoplasms

NCT06457919 2026-02-19

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07410494 2026-02-18

SELECT-CAR-NK

Phase 1/2 Recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Carcinoma, Hepatocellular, Liver Neoplasms, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute

NCT07410676 2026-02-18

EBNK-ST-001

Phase 1/2 Recruiting

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06236139 2026-02-17

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06661902 2026-02-17

BURN

Phase 1/2 Completed

Prostatic Neoplasms

NCT07414940 2026-02-17

ACT-RESoLUTE

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT01543659 2026-02-13

Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Phase 1/2 Completed

Prostatic Neoplasms

NCT04946370 2026-02-03

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT03543189 2026-01-29

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Phase 1/2 Active not recruiting

Prostatic Diseases, Prostatic Neoplasms

NCT03553602 2026-01-29

BEACON

Phase 1/2 Terminated

3 enrolled 7 charts

Prostatic Neoplasms

NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT05968144 2026-01-27

ADRIAN

Phase 1/2 Active not recruiting

BreastGenitourinary

Frailty, Breast Neoplasms, Prostatic Neoplasms

NCT07363382 2026-01-23

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

Phase 1/2 Recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT07363486 2026-01-23

Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT07292168 2026-01-21

TAGNOT

Phase 1/2 Recruiting

BreastGenitourinaryHead & NeckThoracic

Acrocephalosyndactylia, Breast Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms

NCT06600698 2026-01-07

Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06970119 2026-01-07

A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06616155 2025-12-08

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT07002320 2025-12-04

ASpiRE

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06574880 2025-11-24

STARLiT

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06615752 2025-11-12

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT03217747 2025-10-23

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Phase 1/2 Active not recruiting

173 enrolled 28 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT05540392 2025-10-10

An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues

Phase 1/2 Active not recruiting

Prostatic Neoplasms, Nocturia

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT05113537 2025-09-18

UPLIFT

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT03042468 2025-09-17

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Phase 1/2 Active not recruiting

50 enrolled 19 charts

Prostatic Neoplasms

NCT05230251 2025-09-12

ROADSTER

Phase 1/2 Completed

Prostatic Neoplasms

NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT01688492 2025-08-12

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT07117760 2025-08-12

Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT07056790 2025-07-09

Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT04886986 2025-06-27

Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Suspended

Prostatic Neoplasms

NCT03712371 2025-06-10

Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients

Phase 1/2 Terminated

12 enrolled 9 charts

Prostatic Neoplasms

NCT04194554 2025-06-04

ASCLEPIuS

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT01848067 2025-05-04

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

9 enrolled 9 charts

Prostatic Neoplasms

NCT03689699 2025-04-29

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

Phase 1/2 Active not recruiting

59 enrolled 9 charts

Prostatic Neoplasms

NCT04619069 2025-04-17

Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05521412 2025-04-06

VIOLET

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT05896371 2025-03-30

PRODIGY-1

Phase 1/2 Not yet recruiting

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT05383079 2025-02-07

AlphaBet

Phase 1/2 Active not recruiting

Prostatic Neoplasms